Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Furosemide
Drug ID BADD_D00979
Description Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative.[L7958] Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.[L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients.[A182495] The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.[L7958]
Indications and Usage Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.[L7958] Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.[L9659] Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.[L7958]
Marketing Status approved; vet_approved
ATC Code C03CA01
DrugBank ID DB00695
KEGG ID D00331
MeSH ID D005665
PubChem ID 3440
TTD Drug ID D0PQ3G
NDC Product Code 72603-474; 51552-0940; 51927-0077; 53002-4300; 55150-323; 61919-442; 63323-280; 63629-1120; 0378-0208; 0404-9864; 68083-432; 68083-433; 68083-434; 0409-6102; 70121-1076; 70860-302; 70934-737; 71335-0384; 71872-7236; 0615-8369; 0904-7177; 36000-063; 43063-849; 51655-310; 55154-9582; 66432-549; 67296-1469; 68071-1708; 68071-1809; 68071-4445; 69315-118; 70756-619; 72789-032; 63415-0025; 43063-806; 43353-747; 43547-402; 51079-073; 51662-1572; 60760-708; 63187-097; 63187-437; 63187-739; 69844-051; 70518-0050; 70518-0251; 70756-620; 70934-111; 0054-4297; 0054-4301; 0054-8297; 71872-7295; 60760-707; 63187-517; 63629-1216; 0378-0232; 64980-564; 67296-1547; 68071-3461; 68788-7354; 69315-116; 0054-3294; 71335-0842; 71335-1632; 0054-8299; 71610-636; 71872-7277; 72789-033; 72789-157; 42291-468; 42708-174; 43353-018; 43353-341; 43547-401; 50090-2560; 51407-113; 51407-114; 51662-1336; 52584-284; 63629-1119; 63629-1217; 64980-562; 0404-9863; 68094-756; 68094-867; 69315-117; 69844-052; 70121-1163; 70529-550; 71335-0397; 71872-7278; 49452-3222; 57451-0007; 36000-283; 43353-069; 50090-5429; 51655-481; 51662-1226; 51662-1574; 58118-0143; 60760-858; 70121-1164; 70518-0809; 70518-2766; 70529-061; 0054-3298; 72789-030; 48087-0053; 51927-1784; 71052-238; 30698-060; 30698-067; 36000-282; 60760-217; 61919-255; 63629-1215; 0378-0216; 64679-759; 68071-2313; 68071-3273; 70518-0836; 70529-062; 70529-549; 0054-8301; 71610-096; 71610-635; 0615-8370; 72603-251; 83284-002; 16729-500; 25021-311; 36000-284; 43547-403; 50090-5702; 50090-6219; 50090-6221; 51662-1227; 63187-506; 68071-4022; 71610-049; 17337-0087; 72166-003; 16729-502; 23155-473; 42708-123; 43063-702; 50090-3313; 50090-3338; 51079-072; 51079-527; 51407-115; 52584-283; 55150-322; 55150-324; 55154-2365; 63187-790; 63629-1214; 66432-550; 68071-3459; 68788-6784; 70518-3757; 70756-618; 0054-4299; 71288-203; 71335-0601; 71610-634; 71872-7127; 72572-190; 0904-7178; 57451-0006; 66326-401; 70193-0002; 42291-469; 53808-1109; 55154-4452; 55154-9581; 55700-452; 61919-242; 64980-563; 0404-9862; 0409-1639; 68788-6948; 68788-7265; 69844-053; 70518-3061; 71335-0852; 71610-284; 71872-7059; 0615-8368; 72603-133; 81565-201; 48087-0054; 51927-0078; 82348-105; 16729-501; 17224-178; 30698-066; 36000-064; 36000-065; 42291-470; 43063-716; 50090-3339; 51662-1575; 55154-2364; 55700-461
UNII 7LXU5N7ZO5
Synonyms Furosemide | Frusemide | Fursemide | Frusemid | Fusid | Lasix | Furosemide Monohydrochloride | Errolon | Furanthril | Furantral | Furosemide Monosodium Salt
Chemical Information
Molecular Formula C12H11ClN2O5S
CAS Registry Number 54-31-9
SMILES C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Therapeutic response decreased08.06.01.0160.000157%Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.0050.000028%
Tinnitus17.04.07.004; 04.04.01.002--
Tongue discolouration07.14.02.0060.000031%Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000021%Not Available
Torsade de pointes02.03.04.0050.000160%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000090%
Ulcer08.03.06.0010.000014%Not Available
Urate nephropathy20.05.03.014; 14.09.01.0080.000014%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000042%
Urinary retention20.02.02.0110.000103%
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 01.01.04.007; 23.06.01.008--Not Available
Vasculitis24.12.04.027; 10.02.02.0060.000028%
Vasculitis necrotising24.12.04.029; 10.02.02.008--Not Available
Venous thrombosis24.01.01.0080.000014%Not Available
Ventricular extrasystoles02.03.04.0070.000042%Not Available
Ventricular fibrillation02.03.04.0080.000146%
Ventricular tachycardia02.03.04.0100.000083%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vitamin D deficiency14.12.03.0030.000014%Not Available
Vitreous haemorrhage24.07.05.005; 06.10.03.0010.000014%
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene